Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 3/20 | 0.58 |
| ▸ | MAOB | P27338 | 3/20 | 0.58 |
| ▸ | CALML3 | P27482 | 6/20 | 0.56 |
| ▸ | GRM2 | Q14416 | 3/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | FADS1 | O60427 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3430334 | 1.00 | MAOA (0.58) | MAOAMAOBCALML3GRM2CYP2C19 | |
| SCHEMBL1557298 | 0.85 | MAOA (0.71) | MAOAMAOBCALML3GRM2CYP2C19 | |
| SCHEMBL3087781 | 0.85 | MAOA (0.71) | MAOAMAOBCALML3GRM2CYP2C19 | |
| SCHEMBL1032517 | 0.85 | MAOA (0.71) | MAOAMAOBCALML3GRM2CYP2C19 | |
| SCHEMBL30063909 | 0.85 | MAOA (0.71) | MAOAMAOBCALML3GRM2CYP2C19 | |
| SCHEMBL2901464 | 0.84 | F10 (0.52) | MAOAMAOBCALML3GRM2FADS1 | |
| SCHEMBL2896810 | 0.84 | F10 (0.52) | MAOAMAOBCALML3GRM2FADS1 | |
| SCHEMBL8594735 | 0.84 | GRM2 (0.48) | MAOAMAOBCALML3GRM2FADS1 | |
| SCHEMBL7297166 | 0.84 | GRM2 (0.63) | MAOAMAOBCALML3GRM2FADS1 | |
| SCHEMBL412867 | 0.84 | CALML3 (0.62) | MAOAMAOBCALML3CYP2C19CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1646629-B1 | CYCLOPROPYL GROUP SUBSTITUTED OXAZOLIDINONE ANTIBIOTICS AND DERIVATIVES THEREOF | MERCK SHARP & DOHME (US) | 2010-06-23 | — | — | EP | disclosed |
| US-7582659-B2 | Cyclopropyl group substituted oxazolidinone antibiotics and derivatives thereof | MERCK & CO., INC. (US) | 2009-09-01 | — | — | US | disclosed |
| US-7462633-B2 | Cyclopropyl group substituted oxazolidinone antibiotics and derivatives thereof | MERCK & CO., INC. (US) | 2008-12-09 | — | — | US | disclosed |
| US-20070203187-A1 | Cyclopropyl group substituted oxazolidinone antibiotics and derivatives thereof | MERCK & CO., INC. (US) | 2007-08-30 | — | — | US | disclosed |
| US-20050038092-A1 | Cyclopropyl group substituted oxazolidinone antibiotics and derivatives thereof | MERCK SHARP & DOHME CORP. | 2005-02-17 | — | — | US | disclosed |
| US-20030216374-A1 | Antibiotic oxazolidinone derivatives | SYNGENTA LIMITED (GB) | 2003-11-20 | — | — | US | disclosed |
| US-6605630-B1 | Active against drug resistant gram positive pathogens | SYNGENTA LIMITED (GB) | 2003-08-12 | — | — | US | disclosed |
| EP-1005468-A1 | ANTIBIOTIC OXAZOLIDINONE DERIVATIVES | ZENECA LIMITED (GB) | 2000-06-07 | — | — | EP | disclosed |
| WO-1999010342-A1 | ANTIBIOTIC OXAZOLIDINONE DERIVATIVES | ZENECA LIMITED (GB) | 1999-03-04 | — | — | WO | disclosed |
| EP-0673370-B1 | TROPONE-SUBSTITUTED PHENYLOXAZOLIDINONE ANTIBACTERIAL AGENTS | UPJOHN CO (US) | 1998-01-07 | — | — | EP | disclosed |
| US-5523403-A | Tropone-substituted phenyloxazolidinone antibacterial agents | THE UPJOHN COMPANY (US) | 1996-06-04 | — | — | US | disclosed |
| EP-0673370-A1 | TROPONE-SUBSTITUTED PHENYLOXAZOLIDINONE ANTIBACTERIAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 1995-09-27 | — | — | EP | disclosed |
| CN-1092413-A | The phenyloxazolidinone antibacterial agents that tropone replaces | UPJOHN CO (US) | 1994-09-21 | — | — | CN | disclosed |
| WO-1994013649-A1 | TROPONE-SUBSTITUTED PHENYLOXAZOLIDINONE ANTIBACTERIAL AGENTS | THE UPJOHN COMPANY (US) | 1994-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203187-A1 | Cyclopropyl group substituted oxazolidinone antibiotics and derivatives thereof | OXA1L, ALAD, COASY | MAOA 2977/4885MAOB 1835/4885CALML3 3370/4885 |
| US-20050038092-A1 | Cyclopropyl group substituted oxazolidinone antibiotics and derivatives thereof | OXA1L, ALAD, COASY | MAOA 2977/4885MAOB 1835/4885CALML3 3370/4885 |
| US-20030216374-A1 | Antibiotic oxazolidinone derivatives | OXA1L, HRH1, OGDH | MAOA 1078/4885MAOB 386/4885CALML3 4822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.